TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Hyperbaric Oxygen Therapy on Clinical Symptoms and Markers of Inflammation and Oxidative Stress in Autistic Children: A Pilot Study
Brief Summary: Autism is a neurodevelopmental disorder that currently affects as many as 1 out of 166 children in the United States. Autism is considered by many to be a permanent condition with little hope for improvement. Treatment for autism is centered on special schooling and behavioral therapy; medical science currently has little to offer.

Recent research has discovered that some autistic individuals have decreased blood flow to the brain, evidence of inflammation in the brain, and increased markers of oxidative stress. Multiple independent single photon emission computed tomography (SPECT) and positron emission tomography (PET) research studies have revealed hypoperfusion to several areas of the autistic brain, most notably the temporal regions and areas specifically related to language comprehension and auditory processing. Several studies show that diminished blood flow to these areas correlates with many of the clinical features associated with autism including repetitive, self-stimulatory and stereotypical behaviors, and impairments in communication, sensory perception, and social interaction. Hyperbaric oxygen therapy (HBOT) has been used with clinical success in several cerebral hypoperfusion syndromes including cerebral palsy, fetal alcohol syndrome, closed head injury, and stroke. HBOT can compensate for decreased blood flow by increasing the oxygen content of plasma and body tissues and can even normalize oxygen levels in ischemic tissue. In addition, animal studies have shown that HBOT has potent anti-inflammatory effects and reduces oxidative stress. Furthermore, recent evidence demonstrates that HBOT mobilizes stem cells from human bone marrow which may aid recovery in neurodegenerative diseases. Based upon these findings, it is hypothesized that HBOT will improve symptoms in autistic individuals.

The purpose of this study is to determine if HBOT improves clinical outcomes in children with autism. The study will also determine if HBOT changes markers of inflammation and oxidative stress in autistic children.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Hyperbaric Oxygen Treatment (HBOT) | Intervention Type: OTHER; Name: Hyperbaric Oxygen Treatment (HBOT); Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Hyperbaric Oxygen Therapy; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Hyperbaric Oxygen Therapy; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: Hyperbaric Therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing the Safety and Efficacy of Lansoprazole Microgranules Oral Suspension in Infants With Symptomatic Gastroesophageal Reflux
Brief Summary: The purpose of this study is to assess the safety and efficacy of lansoprazole microgranules oral suspension, once daily (QD), in infants with gastroesophageal reflux symptoms during a 4-week treatment period.


Options:
A: Arm Label: Rabeprazole 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Arm Label: Rabeprazole 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: rabeprazole | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 0.5 mg/kg | Intervention Type: DRUG; Name: rabeprazole; Assigned to Arm(s): Rabeprazole 1.0 mg/kg
B: Arm Label: Lansoprazole QD; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole microgranules suspension | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lansoprazole microgranules suspension; Assigned to Arm(s): Lansoprazole QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
C: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Esomeprazole (Nexium); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing the Safety and Efficacy of Lansoprazole Microgranules Oral Suspension in Infants With Symptomatic Gastroesophageal Reflux
Brief Summary: The purpose of this study is to assess the safety and efficacy of lansoprazole microgranules oral suspension, once daily (QD), in infants with gastroesophageal reflux symptoms during a 4-week treatment period.


Options:
A: Arm Label: Lansoprazole QD; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole microgranules suspension | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lansoprazole microgranules suspension; Assigned to Arm(s): Lansoprazole QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
B: Intervention Type: DRUG; Name: pantoprazole for approximately 9 weeks.; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
D: Arm Label: Open Label Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Open Label Run In Esomeprazole | Arm Label: Double Blind Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Double Blind Esomeprazole | Arm Label: Double Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double Blind Placebo | Intervention Type: DRUG; Name: Open Label Run In Esomeprazole; Assigned to Arm(s): Open Label Esomeprazole | Intervention Type: DRUG; Name: Double Blind Esomeprazole; Assigned to Arm(s): Double Blind Esomeprazole | Intervention Type: DRUG; Name: Double Blind Placebo; Assigned to Arm(s): Double Blind Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TOMUS-Trial Of Mid-Urethral Slings
Brief Summary: The primary aim of this clinical trial is to compare treatment success for two minimally invasive surgical procedures to treat stress urinary incontinence in women. These procedures are called mid-urethral slings. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and the need for other treatments(s) after surgery. Follow-up will be a minimum of two years.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: retropubic mid-urethral sling (TVT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transobturator mid-urethral sling (TVT-O and the Monarc) | Intervention Type: PROCEDURE; Name: retropubic mid-urethral sling (TVT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: transobturator mid-urethral sling (TVT-O and the Monarc); Assigned to Arm(s): 2
B: Arm Label: Abdominal Sacral Colpopexy with no Burch colposuspension; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Abdominal Sacral Colpopexy with Burch Colposuspension; Type: EXPERIMENTAL; Interventions: Procedure: Burch urethropexy at time of sacrocolpopexy | Intervention Type: PROCEDURE; Name: Burch urethropexy at time of sacrocolpopexy; Assigned to Arm(s): Abdominal Sacral Colpopexy with Burch Colposuspension
C: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
D: Arm Label: Abdominal Sacral Colpopexy with no Burch colposuspension; Type: N/A; Interventions: N/A | Arm Label: Abdominal Sacral Colpopexy with Burch Colposuspension; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TOMUS-Trial Of Mid-Urethral Slings
Brief Summary: The primary aim of this clinical trial is to compare treatment success for two minimally invasive surgical procedures to treat stress urinary incontinence in women. These procedures are called mid-urethral slings. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and the need for other treatments(s) after surgery. Follow-up will be a minimum of two years.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: retropubic mid-urethral sling (TVT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transobturator mid-urethral sling (TVT-O and the Monarc) | Intervention Type: PROCEDURE; Name: retropubic mid-urethral sling (TVT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: transobturator mid-urethral sling (TVT-O and the Monarc); Assigned to Arm(s): 2
B: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
C: Arm Label: 2; Type: N/A; Interventions: Procedure: AFS and TVT | Intervention Type: PROCEDURE; Name: AFS and TVT; Assigned to Arm(s): 2
D: Arm Label: Autologous Fascial Sling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Autologous fascial sling | Arm Label: TVT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: TVT | Arm Label: Pelvicol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pelvicol | Intervention Type: PROCEDURE; Name: Autologous fascial sling; Assigned to Arm(s): Autologous Fascial Sling | Intervention Type: PROCEDURE; Name: TVT; Assigned to Arm(s): TVT | Intervention Type: PROCEDURE; Name: Pelvicol; Assigned to Arm(s): Pelvicol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double Dummy, 3 Way Crossover Study Evaluating the Effects of a Combination of Seretide 50/500mcg Twice Daily Plus Tiotropium Bromide 18mcg Once Daily Compared With the Individual Agents (Tiotropium Bromide 18mcg Alone and Seretide50/500mcg Alone) in the Treatment of Subjects With COPD
Brief Summary: This study was designed to evaluate the effects on lung function of a combination of SERETIDE 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg once daily alone and SERETIDE 50/500mcg twice daily alone) in subjects with COPD. The study will utilise a three-way cross-over design with a 2-week wash-out period between each 2-week consecutive treatment period.


Options:
A: Arm Label: N/A (Survey study); Type: N/A; Interventions: Other: Non-Interventional | Intervention Type: OTHER; Name: Non-Interventional; Assigned to Arm(s): N/A (Survey study)
B: Arm Label: fluticasone propionate/salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate/salmeterol 50/250mcg, Drug: tiotropium bromide placebo, Drug: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg | Arm Label: tiotropium bromide; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate/salmeterol placebo, Drug: tiotropium bromide 18mcg, Drug: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg | Intervention Type: DRUG; Name: fluticasone propionate/salmeterol 50/250mcg; Assigned to Arm(s): fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: fluticasone propionate/salmeterol placebo; Assigned to Arm(s): tiotropium bromide | Intervention Type: DRUG; Name: tiotropium bromide 18mcg; Assigned to Arm(s): tiotropium bromide | Intervention Type: DRUG; Name: tiotropium bromide placebo; Assigned to Arm(s): fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg; Assigned to Arm(s): fluticasone propionate/salmeterol, tiotropium bromide
C: Intervention Type: DRUG; Name: Tiotropium + SERETIDE 50/500; Assigned to Arm(s): N/A
D: Arm Label: ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate/Salmeterol | Arm Label: SPIRIVA® HANDIHALER® inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium Bromide | Intervention Type: DRUG; Name: Tiotropium Bromide; Assigned to Arm(s): SPIRIVA® HANDIHALER® inhaler | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol; Assigned to Arm(s): ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout
Brief Summary: These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who are unable to take standard gout therapies, or for whom those therapies have been unsuccessful in controlling their uric acid level.


Options:
A: Arm Label: q2 RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: q4 RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: Placebo in RCT; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Intervention Type: BIOLOGICAL; Name: pegloticase; Assigned to Arm(s): Placebo in RCT, q2 RCT, q4 RCT
B: Arm Label: Febuxostat 40 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol 200 mg or 300 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 40 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol 200 mg or 300 mg QD
C: Intervention Type: DRUG; Name: Oxypurinol; Assigned to Arm(s): N/A
D: Arm Label: q2 wks; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: q4 wks; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: BIOLOGICAL; Name: pegloticase; Assigned to Arm(s): q2 wks, q4 wks

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: It is increasingly recognised that rapid growth in infancy may be associated with a greater risk of cardiovascular disease later in life. This trial will investigate whether the use of infant feeding bottles with different designs influences the milk intake and growth of infants. We will compare the growth of bottle-fed infants with that of a breast-fed reference group.


Options:
A: Arm Label: Patterned Experience Group; Type: EXPERIMENTAL; Interventions: Behavioral: Patterned Experience | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patterned Experience; Assigned to Arm(s): Patterned Experience Group
B: Arm Label: skin to skin contact; Type: EXPERIMENTAL; Interventions: Other: skin to skin contact | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Other: Control group | Intervention Type: OTHER; Name: skin to skin contact; Assigned to Arm(s): skin to skin contact | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
C: Intervention Type: DEVICE; Name: partial-vacuum milk bottle; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: anti-vacuum milk bottle; Assigned to Arm(s): N/A
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention group | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Short Course Zinc Therapy (5 vs 10 d) With 20 mg Elemental Zinc Daily in the Treatment of Acute Diarrhoea: A Double-blind Individually Randomized Controlled Community Trial.
Brief Summary: Diarrhoea continues to be a major cause of mortality and morbidity in young children especially in many developing countries. Although the mortality burden of diarrhoea has substantially reduced, the morbidity pattern remained almost unchanged. Recent randomized controlled supplementation trials in developing countries have consistently shown that zinc has the potential to reduce the duration of diarrhoea as well as has preventive effect on childhood diarhroea in subsequent months. Currently, international health agencies recommend zinc as an important adjunct therapy to treat diarrhoea in developing countries where zinc deficiency is highly prevalent and diet is poor in zinc.

The recommendation is to provide 20 mg elemental zinc daily for 10 days during each episode of diarrhoea.

This study aims at evaluating the relative efficacy of two length of 20 mg zinc therapy (5 vs 10 days) during acute diarrhoea in a rural community in a community-based individually randomized placebo-controlled trial with 20 mg zinc daily and will be conducted in seven villages in the ICDDR,B Matlab study area.

The study will require 2050 acute dirrhoeal episodes to be treated who will be randomly allocated to one of the two treatment schedules (20 mg of zinc daily for 5 or 10 days). Children who will be allocated to the shorter duration therapy will receive placebo for the remaining days to complete 10-day treatment. Female Field Workers (FFWs) will conduct diarrhoea surveillance and administer zinc daily at home. Data will be analyzed using appropriate statistical procedure.

Findings of this study will be immensely valuable for deciding recommendation for the duration of zinc therapy in the management of acute diarrhoea in young children and will have profound programmatic and policy implications for scaling up zinc intervention in the community.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Lyophilized meat | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Cereal | Intervention Type: OTHER; Name: Lyophilized meat; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Cereal; Assigned to Arm(s): 2
B: Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Drug: Zinc (zinc sulphate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Drug: Zinc (zinc sulphate); Assigned to Arm(s): Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: ZINC; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Short Course Zinc Therapy (5 vs 10 d) With 20 mg Elemental Zinc Daily in the Treatment of Acute Diarrhoea: A Double-blind Individually Randomized Controlled Community Trial.
Brief Summary: Diarrhoea continues to be a major cause of mortality and morbidity in young children especially in many developing countries. Although the mortality burden of diarrhoea has substantially reduced, the morbidity pattern remained almost unchanged. Recent randomized controlled supplementation trials in developing countries have consistently shown that zinc has the potential to reduce the duration of diarrhoea as well as has preventive effect on childhood diarhroea in subsequent months. Currently, international health agencies recommend zinc as an important adjunct therapy to treat diarrhoea in developing countries where zinc deficiency is highly prevalent and diet is poor in zinc.

The recommendation is to provide 20 mg elemental zinc daily for 10 days during each episode of diarrhoea.

This study aims at evaluating the relative efficacy of two length of 20 mg zinc therapy (5 vs 10 days) during acute diarrhoea in a rural community in a community-based individually randomized placebo-controlled trial with 20 mg zinc daily and will be conducted in seven villages in the ICDDR,B Matlab study area.

The study will require 2050 acute dirrhoeal episodes to be treated who will be randomly allocated to one of the two treatment schedules (20 mg of zinc daily for 5 or 10 days). Children who will be allocated to the shorter duration therapy will receive placebo for the remaining days to complete 10-day treatment. Female Field Workers (FFWs) will conduct diarrhoea surveillance and administer zinc daily at home. Data will be analyzed using appropriate statistical procedure.

Findings of this study will be immensely valuable for deciding recommendation for the duration of zinc therapy in the management of acute diarrhoea in young children and will have profound programmatic and policy implications for scaling up zinc intervention in the community.


Options:
A: Arm Label: X: Zinc sulphate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc sulphate | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc sulphate; Assigned to Arm(s): X: Zinc sulphate
B: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: ZINC; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.; Assigned to Arm(s): N/A

Answer: C